Akari Therapeutics plc ADS (AKTX)
AKTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AKTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001541157 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements." | 10-Q 2026-11-12 |
| Cash and burn | $5.7M cash; operating cash flow -$3.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,326,149 (2026-11-12); 893,493 a year earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-17 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2025-11-26 |
| Auditor | BDO USA, P.C., New York, New York, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-05-18 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$4.8M | -$4.2M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$4.8M | -$3.1M | $7.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$14.5M | -$2.5M | $2.8M | $49K | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$5.3M | -$3.0M | $5.2M | $81K | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$6.4M | -$2.1M | $2.5M | $198K | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$1.9M | -$3.3M | $2.7M | $179K | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$3.7M | -$2.1M | $2.6M | $228K | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$3.8M | -$2.1M | $0 | $659K | Needs four quarters | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-07-02 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-10-01 |
Source: SEC EDGAR submissions feed, 747 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.7% |
| 1 month | -13.9% |
| 3 months | -2.9% |
| Year to date | -41.2% |
| 1 year | -67.3% |
| From 52-week high | -69.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| CNTX | Context Therapeutics Inc. | $0.1659 | -8.24% | $15.2M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| NCEL | NewcelX Ltd. | $2.75 | +5.36% | $15.9M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier